Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Post by ValueCapon Jan 09, 2020 11:55pm
354 Views
Post# 30537469

Bloom Burton Recent Release

Bloom Burton Recent ReleaseNot much change, but my opinion is just put a conservative 5-7x multiple on EBITDA - as a benchmark, what they acquired the Aralez assets for - and that EBITDA estimate doesn't include anything of the Resultz US, Suvexx or EU P2%. Company valuation upside accrues to the equity holder from these prices. As debt gets paid down further value enterprise value accrues to the equity holder. 

https://www.bloomburton.com/research/NRI20200108.pdf
<< Previous
Bullboard Posts
Next >>